Replimune Group, Inc. announced changes to its executive leadership team designed to support the company?s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Mr. Philip Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors. Additional changes include: Robert Coffin, Ph.D., Founder, President and Chief Research & Development Officer will move to an advisory role as Founder and Chief Scientist and will continue to serve on the Board of Directors; Paul Bullock is being appointed Chief Manufacturing Officer and will assume oversight of manufacturing and lead operations in Framingham and Milton Park in the United Kingdom, following the retirement of Colin Love, Ph.D., Chief Operations Officer, and co-founder, who established its manufacturing operations; Pamela Esposito, Ph.D., Chief Business Officer, and Tanya Lewis, Chief Development Operations Officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity.